Status:

COMPLETED

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Adenocarcinoma of the Prostate

Stage I Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE1

Brief Summary

Green tea extract contains ingredients that may prevent or slow the growth of prostate cancer. This phase I trial is studying how well green tea extract works in treating patients with prostate cancer...

Detailed Description

PRIMARY OBJECTIVES: I. Determine the bioavailability of defined green tea catechin extract in prostate tissue after treatment with defined green tea extract in patients with prostate cancer. SECONDA...

Eligibility Criteria

Inclusion

  • Criteria:
  • Biopsy-proven adenocarcinoma of the prostate meeting the following criteria: organ-confined disease; treatable by prostatectomy
  • PSA \< 50 ng/mL
  • ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
  • Bilirubin normal
  • AST and ALT normal
  • Creatinine normal
  • Fertile patients must use effective contraception
  • No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; psychiatric illness or social situations that would limit study compliance
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extract
  • No prior therapy for prostate cancer (i.e., hormone therapy, radiation therapy, or surgery)
  • No systemic treatment (chemotherapy) and/or radiation therapy for any malignancy within the past 5 years (excluding nonmelanoma skin cancer or cancer confined to organs with surgical removal as the only treatment)
  • No regular tea consumption (\> 6 servings of hot tea or 12 servings of iced tea or equivalent combination per week) within the past month
  • No other concurrent investigational agents
  • No other concurrent consumption of tea or tea-derived products from green, black, or oolong tea

Exclusion

    Key Trial Info

    Start Date :

    March 1 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2010

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT00459407

    Start Date

    March 1 2007

    End Date

    August 1 2010

    Last Update

    October 8 2014

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Arizona Cancer Center - Tucson

    Tucson, Arizona, United States, 85724-5024